Exploring In Vitro Markers of Potency of Extracellular Vesicles From Cardiosphere-Derived Cells in the Treatment of Cardiac Aging

    October 2022 in “ European Heart Journal ”
    L Gómez-Cid, M Cervera-Negueruela, A Campo-Fonseca, S Suárez-Sancho, A Pinto, Juan Miguel Gil Jaúrena, María Eugenia Fernández‐Santos, Francisco Fernández‐Avilés, Lilián Grigorian-Shamagian
    TLDR Potent extracellular vesicles from cardiosphere-derived cells can improve heart health and other functions in aging.
    The study investigates the potential of extracellular vesicles (EVs) derived from cardiosphere-derived cells (CDCs) in treating cardiac aging. Researchers characterized CDCs from 34 patients, assessing their senescence, proliferative and migration capacities, and other properties. EVs were classified as potent (P-EVs) or non-potent (NP-EVs) based on their anti-senescent and pro-angiogenic effects in vitro. In vivo tests on rats with induced cardiac aging showed that P-EVs, but not NP-EVs, prevented hypertrophy and improved several cardiac and systemic parameters, including glucose metabolism and hair growth. The study suggests that the proposed potency assay could predict the suitability of EVs for treating cardiac aging.
    Discuss this study in the Community →